Anthony El-Khoueiry
University of Southern California · USC Norris and HOAG sites · University of Southern California, Norris
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Anthony El-Khoueiry as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:46 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07337525 · A First in Human Study of PLT012 in Participants With Solid Tumor CancersPilatus Biosciences Inc · recruiting · Advanced Malignant Solid Tumor, Solid Tumor Cancer · principal investigator
- Ph1NCT05037149 · Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid TumorsSirnaomics · completed · Solid Tumor · principal investigator
- Ph1NCT03537690 · FID-007 in Treating Participants With Advanced Solid TumorsUniversity of Southern California · active not recruiting · Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm · principal investigator
- Ph1NCT03257761 · Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerUniversity of Southern California · active not recruiting · Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma · principal investigator
- Ph1/Ph2NCT03058289 · A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6Intensity Therapeutics, Inc. · completed · Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma · principal investigator
- Ph1NCT02495896 · Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid TumorsUniversity of Southern California · active not recruiting · Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma · principal investigator
- Ph1NCT01957995 · Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid TumorsUniversity of Southern California · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1NCT01779336 · Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid TumorsPiramal Enterprises Limited · suspended · Advanced Refractory Solid Tumors · principal investigator
- Ph1NCT01762410 · Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid TumorsPiramal Enterprises Limited · suspended · Advanced Refractory Solid Tumors · principal investigator
- Ph1NCT01642342 · Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid TumorsUniversity of Southern California · terminated · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1NCT01302405 · Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid TumorsPrism Pharma Co., Ltd. · terminated · Advanced Solid Tumors · principal investigator
- Ph2NCT01239355 · MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous TherapyNational Cancer Institute (NCI) · terminated · Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma · principal investigator
- Ph2NCT01093222 · Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or CholangiocarcinomaNational Cancer Institute (NCI) · completed · Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia · principal investigator
- Ph1NCT00667147 · Phase I Abraxane Weekly and Three Weekly Schedule With VandetanibUniversity of Southern California · completed · Solid Tumors · principal investigator
- Ph2NCT00238212 · S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaNational Cancer Institute (NCI) · completed · Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- NCTN - Network Lead Academic Participating Site: USCUG1CA180830 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 2019 to 2026 · $218,746 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Protocol and Data ManagementP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 2016 to 2024 · $656,287 awarded in 2024Grant number is on one of their registry trials
- Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitorsU01AA027681 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2018 to 2022 · $725,319 awarded in 2022Same name and institution; not confirmed by an ID
- NCI NCTN- Network Lead Academic Participating Site: USCU10CA180830 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 2014 to 2018 · $523,827 awarded in 2018Same name and institution; not confirmed by an ID
- CLINICAL TRIAL: PHASE I TRIAL OF 5-FLUORO-2'-DEOXYCYTIDINE WITH TETRAHYDROURIDINM01RR000043 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 2009 · $2,320 awarded in 2009Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2008 to 2026Named on NCT01239355
- Southwest Oncology Group Treatment GrantU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 2008 to 2013Named on NCT01093222
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:46 UTC. The ranking covers the 200 most relevant of 72 PubMed records, and a shared surname and initials can bring in a namesake. All 72 on PubMed
- 3,555 citationsRCR 120.7
- 1,937 citationsRCR 71.8
- 1,132 citationsRCR 49.6
- Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol · 20221,010 citationsRCR 72.7
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol · 2020931 citationsRCR 37.6
- 779 citationsRCR 25.4
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.J Clin Oncol · 2018541 citationsRCR 17.7
- 432 citationsRCR 22.7
- Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Lancet Gastroenterol Hepatol · 2021357 citationsRCR 19.4
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.J Hepatol · 2020352 citationsRCR 13.5